Reading SINT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SINT free→
SINTX TECHNOLOGIES INC (SINT)
NASDAQHealth CareMedical DevicesSnapshot 2026-06-16
Watch· this week
$2.17-1.81%
Close 2026-06-16 · 1-day change
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
The bottom line
Recent financial performance is neutral, and management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed, and it trades below typical for sector peers. Peer multiples imply a price about 98% below where it trades (it looks expensive on this basis); the read is rich. The outlook hinges on sector bellwethers like ABT, SYK, and MDT, as their earnings performance could influence SINT's momentum. This read is provisional.
as of 2026-06-16
Quick facts
- Exchange
- NASDAQ
- Sector
- Health Care
- Industry
- Medical Devices
- Market cap
- $13.71M
- Employees
- —
- IPO date
- 2007-05-22
- Next earnings
- —
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 2 valuation methods, at three horizons. Current price $2.17. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryinexpensive
$4.20consensus
Range $3.41 – $5.00
vs price: -48% below
Method agreement — · 2 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearinexpensive
$3.45consensus
Range $2.77 – $4.12
vs price: -37% below
Method agreement — · 2 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearinexpensive
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Re-ratingmedium confidence
At $2.17 SINT trades at 6× p/s — 1.9× the 3× p/s peer median. The market is re-rating it beyond its own range; our $1.85 fair value is medium-confidence here. Not investment advice.
Multiple (P/S)
5.5x
peer 2.9x · own history —
Premium
1.9x peer
Growth the price needs
19%
our forecast -46%
Our fair value
$1.85
range $1.50 – $2.20
WhyEarnings too small for P/E
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
inexpensiverich12-month view
What's priced inUnjustified
The market is pricing in roughly 19% near-term growth, well above our forecast of about -46%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Low fragilityrisk posture, not a price call
No fragility gates fired. Regime (Mania) does not concentrate fragility.
Historical context
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
neutralOperating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
32nd pctl · Health Care
Earnings quality
loss makingOver the trailing year it converted 0.90x of net income into operating cash flow.
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates.
Management & capital allocation
volatile10 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Strongly bearishEPS revised -9.0% / 30d, n=2for period ending 2026-06-30
Why this setup
Consensus revisions
EPS estimate $-0.67 → $-0.73 (-9.0% / 30d). 0 raised, 1 cut, 2 covering analysts.
Rating actions
0 upgrades, 0 downgrades / 30d, 1 maintained. 100% of analysts rate Buy.
Material events
0 positive, 2 negative / 30d. See F4 management tile for the event list.
Sector context
Intermediate · WeeklySector phase: health care is in maturing, with decelerating (~0.5 years in phase).
Sector regime (90d momentum): headwind.Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: weak
- Capital allocation
- weak
- Earnings discipline
- weak
- Margin discipline
- weak
- Balance sheet
- weak
- Post-call reaction
- weak
A guidance track record builds as the company issues and delivers on guidance.
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$206.
How much price usually moves either way.
On a bad day, this stock has moved -$708.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,388.
Deepest peak-to-trough drop in the last year.
highas of 2026-06-16
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- label change · valuation_labelsmall change
Valuation label changed from 'fair' to 'inexpensive'.
The valuation dimension changed. It rose to an expensive label. The company remains unprofitable. Risk is high, and the sector backdrop is a headwind.
as of 2026-06-16
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
- 2026-06-0313d agoInvesting.com
Advances: Conduct private placement for $4.5M
Successful private placement meets capital allocation objective.
Strongly reinforcesConfirmed
This sector is also watching
- Watch for revenue growth re-acceleration in Health Care
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like ABT, SYK, and MDT keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting SINT and other Healthcare names. Worth watching these names for early signals.
- If the Fed starts cutting rates from the current 3.62%, that would be a tailwind for SINT and other Healthcare names, since rate-sensitive parts of the market tend to rally when the Fed eases.
Downside triggers
- If sector bellwethers like ABT, SYK, and MDT start missing or guiding lower, the Healthcare tailwind helping SINT and other Healthcare names could fade. Watch these names for early warning.
- If SINT misses again next quarter like this past one (a miss of -6% on the 2026-03-31 print), expect continued pressure. The Street usually keeps walking estimates down after consecutive misses.
- If GDP growth slows materially from the current 2.6% (say, below 2%), it hits SINT and other Healthcare names harder than the average stock, since the sector is growth-sensitive.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-2721d agoItem 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 22, 2026, SINTX Technologies, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2.5 million in stockholders’ equity for conti…
Legal / regulatorynegative
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
+6.1 vs last weeklatest as of 2026-06-17
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.